Avidity Biosciences, Inc.

RNAM

Avidity Biosciences, Inc.

RNAM

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-01-21Shares Purchased (TTM):0Shares Sold (TTM):237,179

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:8,000Shares Outstanding:137,710,000Institutional Ownership Pct.:0.01%

Earnings Market Reaction:

Filing Date:2026-02-23Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Assets
Cash And Cash Equivalents At Carrying Value	383	350	244	254	220	370	576	471	185	86	154	119
Assets Current
Assets Current	1,798	1,966	1,251	1,435	1,542	1,622	1,329	934	611	555	595	597
Debt Securities Available For Sale Excluding Accru…	1,314	1,526	939	1,126	1,282	1,218	723	444	410	457	423	468
Prepaid Expense And Other Assets Current	102	90	67	55	41	33	30	19	16	13	18	11
Property Plant And Equipment Net	23	22	21	16	13	9	8	9	8	8	8	8
Restricted Cash Noncurrent	3	3	3	3	3	3	3	0	0	0	0	0
Operating Lease Right Of Use Asset	51	53	4	5	6	6	7	8	8	9	8	8
Other Assets Noncurrent	82	91	91	1	1	0	0	0	0	0	0	0
Assets	1,958	2,134	1,369	1,459	1,564	1,641	1,347	951	629	573	611	614
Liabilities And Stockhold…
Accounts Payable And Accrued Liabilities Current	-	-	-	54	70	50	41	37	34	32	32	34
Accounts Payable Current	12	10	4	-	8	-	-	-	-	-	-	-
Accrued Liabilities And Other Liabilities	157	137	95	-	65	-	-	-	-	-	-	-
Liabilities Current
Deferred Compensation Liability Current	-	-	18	13	4	18	13	8	14	11	7	6
Liabilities Current	195	170	135	85	98	91	84	75	81	49	45	48
Operating Lease Liability Current	4	4	4	4	4	4	4	4	4	4	3	3
Contract With Customer Liability Current	22	19	14	14	21	20	27	26	28	2	4	5
Operating Lease Liability Noncurrent	45	46	1	2	3	4	5	5	6	7	6	7
Contract With Customer Liability Noncurrent	29	32	40	43	38	42	38	40	41	0	0	0
Liabilities	269	248	176	130	139	137	126	121	128	56	52	55
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Additional Paid In Capital Common Stock	3,264	3,225	2,357	2,335	2,315	2,287	1,932	1,471	1,071	1,030	1,020	971
Stockholders Equity	1,689	1,886	1,193	1,329	1,425	1,503	1,221	831	501	517	559	559
Accumulated Other Comprehensive Income Loss Net Of…	3	2	2	3	3	7	-0	-0	0	-2	-3	-2
Retained Earnings Accumulated Deficit	-1,578	-1,341	-1,166	-1,009	-893	-791	-710	-640	-571	-510	-458	-411
Liabilities And Stockholders Equity	1,958	2,134	1,369	1,459	1,564	1,641	1,347	951	629	573	611	614
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	400	400	400
Common Stock Shares Issued	151	147	121	121	120	119	109	96	79	74	74	71
Shares Outstanding	151	147	121	121	120	119	109	96	79	74	74	71

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	7.98%	1.19%	26.42%	-1.98%	-9.62%	3.43%	2.56%	3.24%	3.91%	-	-	-
2024	-0.89%	50.74%	77.64%	-6.28%	-9.84%	-3.92%	-9.43%	-36.62%	-37.55%	6.05%	-8.32%	4.37%
2023	-3.30%	-3.82%	-19.34%	-10.86%	-28.56%	-45.46%	49.45%	66.97%	122.14%	55.31%	48.95%	93.32%
2022	-	-	-	-	-	-	-	-	-	-15.49%	-31.14%	-54.35%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Liquidity Ratios
Current Ratio	9.20	11.57	9.26	16.91	15.73	17.76	15.78	12.47	7.58	11.40	13.14	12.42
Quick Ratio	8.68	11.04	8.76	16.26	15.32	17.39	15.43	12.22	7.38	11.14	12.74	12.19
Working Capital	1.60B	1.80B	1.12B	1.35B	1.44B	1.53B	1.24B	859.52M	530.63M	506.77M	549.29M	549.06M
Leverage & Debt
Debt to Equity	0.16	0.13	0.15	0.10	0.10	0.09	0.10	0.15	0.26	0.11	0.09	0.10
Debt Ratio	0.14	0.12	0.13	0.09	0.09	0.08	0.09	0.13	0.20	0.10	0.08	0.09
Efficiency & Turnover
Asset Turnover TTM	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.02	0.02	0.02
Per Share Metrics
Diluted EPS TTM	-4.97	-3.99	-3.52	-2.86	-2.89	-2.27	-2.36	-2.62	-2.91	-2.73	-2.71	-2.73
Free Cash Flow Per Share TTM	-4.82	-4.30	-3.88	-2.83	-2.76	-1.53	-1.49	-1.65	-1.69	-2.42	-2.43	-2.27
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-3,977.30%	-2,934.90%	-4,863.29%	-4,853.43%	-3,477.43%	-3,209.35%	-2,690.64%	-2,347.64%	-2,464.41%	-2,191.00%	-2,126.37%	-2,091.17%
Net Profit Margin TTM	-3,650.39%	-2,634.59%	-4,247.76%	-4,135.99%	-2,957.71%	-2,772.45%	-2,381.82%	-2,103.78%	-2,219.87%	-1,995.34%	-1,974.38%	-1,988.76%
Growth Metrics
Net Revenue Growth (1Y)	72.11%	106.27%	1.23%	-17.87%	13.99%	-0.19%	8.15%	12.50%	3.64%	22.02%	22.68%	14.79%
Net Income Growth (1Y)	112.42%	96.01%	80.53%	61.46%	51.87%	38.69%	30.47%	19.01%	21.97%	24.80%	30.97%	49.65%
EPS Growth (1Y)	72.12%	75.37%	48.92%	8.96%	-0.63%	-16.71%	-12.89%	-3.89%	-12.86%	-10.62%	-8.41%	2.51%
Calculated Values
Free Cash Flow TTM	-663.76M	-592.26M	-502.70M	-365.22M	-307.94M	-188.51M	-158.91M	-143.80M	-123.29M	-178.97M	-173.32M	-159.76M
Net Debt	-385.31M	-352.96M	-246.71M	-257.00M	-222.66M	-372.98M	-578.55M	-471.70M	-185.38M	-85.95M	-154.18M	-118.96M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-01-21Sale

Owner: Hughes, Steven George

Title: Chief Medical Officer

Shares: 4,895

Price/Share: $72.45

Value: $354,642.75

Shares Owned: 31,599

Relationship: Officer

Ownership: Direct

2026-01-21Sale

Owner: Boyce, Sarah

Title: President and CEO

Shares: 14,387

Price/Share: $72.45

Value: $1,042,338.15

Shares Owned: 269,007

Relationship: Director,Officer

Ownership: Direct

2026-01-21Sale

Owner: Mccarthy, Teresa

Title: Chief Human Resources Officer

Shares: 2,929

Price/Share: $72.45

Value: $212,206.05

Shares Owned: 113,938

Relationship: Officer

Ownership: Direct

2026-01-21Sale

Owner: Flanagan, W. Michael

Title: Chief Scientific Officer

Shares: 6,534

Price/Share: $72.45

Value: $473,388.30

Shares Owned: 85,093

Relationship: Officer

Ownership: Direct

2026-01-21Sale

Owner: Maclean, Michael F

Title: Chief Financial Officer

Shares: 4,542

Price/Share: $72.45

Value: $329,067.90

Shares Owned: 59,290

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-01-21	Hughes, Steven George	Officer	Chief Medical Officer	Direct	Sale	4,895	72.45	$354,642.75	31,599	4
2026-01-21	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	14,387	72.45	$1,042,338.15	269,007	4
2026-01-21	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	2,929	72.45	$212,206.05	113,938	4
2026-01-21	Flanagan, W. Michael	Officer	Chief Scientific Officer	Direct	Sale	6,534	72.45	$473,388.30	85,093	4
2026-01-21	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	4,542	72.45	$329,067.90	59,290	4
2026-01-21	Levin, Arthur A	Director	-	Direct	Sale	1,758	72.45	$127,367.10	16,562	4
2026-01-07	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	1,974	72.23	$142,582.02	63,832	4
2026-01-07	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	1,965	72.23	$141,931.95	116,867	4
2026-01-07	Moriarty, John B	Officer	Chief Legal Officer	Direct	Sale	2,374	72.23	$171,474.02	74,557	4
2026-01-07	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	8,576	72.23	$619,444.48	283,394	4
2026-01-07	Calderaro, Charles Iii	Officer	Chief Technical Officer	Direct	Sale	3,727	72.23	$269,201.21	49,797	4
2026-01-07	Flanagan, W. Michael	Officer	Chief Scientific Officer	Direct	Sale	2,373	72.23	$171,401.79	91,627	4
2026-01-07	Hughes, Steven George	Officer	Chief Medical Officer	Direct	Sale	2,373	72.23	$171,401.79	36,494	4
2025-10-22	Hughes, Steven George	Officer	Chief Medical Officer	Direct	Sale	2,209	47.54	$105,015.86	38,867	4
2025-10-15	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	20,000	50.15	$1,003,000.00	97,130	4
2025-10-03	Mosbrooker, Eric	Officer	Chief Commercial Officer	Direct	Sale	6,562	45.38	$297,783.56	55,000	4
2025-09-22	Hughes, Steven George	Officer	Chief Medical Officer	Direct	Sale	2,208	40.58	$89,600.64	38,867	4
2025-09-15	Hughes, Steven George	Officer	Chief Medical Officer	Direct	Sale	1,542	45.41	$70,022.22	38,867	4
2025-09-15	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	15,000	41.41	$621,150.00	97,130	4
2025-09-11	Flanagan, W. Michael	Officer	Chief Scientific Officer	Direct	Sale	20,000	38.94	$778,800.00	80,195	4
2025-09-05	Wilson, Troy Edward	Director	-	Direct	Sale	29,500	50.00	$1,475,000.00	54,425	4
2025-09-05	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	50,000	49.95	$2,497,500.00	305,871	4
2025-09-03	Mosbrooker, Eric	Officer	Chief Commercial Officer	Direct	Sale	6,563	47.07	$308,920.41	55,000	4
2025-09-02	Gallagher, Kathleen P.	Officer	Chief Program Officer	Direct	Sale	188	47.42	$8,914.96	50,204	4
2025-08-28	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	25,000	49.39	$1,234,750.00	305,871	4
2025-08-22	Hughes, Steven George	Officer	Chief Medical Officer	Direct	Sale	2,208	46.40	$102,451.20	38,867	4
2025-08-15	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	10,000	46.56	$465,600.00	97,130	4
2025-08-13	Hughes, Steven George	Officer	Chief Medical Officer	Direct	Sale	1,542	46.66	$71,949.72	38,867	4
2025-08-06	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	30,914	42.73	$1,320,955.22	65,806	4
2025-08-06	Levin, Arthur A	Director	-	Direct	Sale	107,500	47.62	$5,119,150.00	19,650	4
2025-08-06	Hughes, Steven George	Officer	Chief Medical Officer	Direct	Sale	81,434	42.74	$3,480,489.16	38,867	4
2025-08-06	Wilson, Troy Edward	Director	-	Direct	Sale	29,500	45.00	$1,327,500.00	69,425	4
2025-08-06	Mosbrooker, Eric	Officer	Chief Commercial Officer	Direct	Sale	130,807	44.06	$5,763,356.42	55,000	4
2025-08-04	Moriarty, John B	Officer	Chief Legal Officer	Direct	Sale	2,245	36.21	$81,291.45	47,755	4
2025-06-17	Gallagher, Kathleen P.	Officer	Chief Program Officer	Direct	Sale	911	30.24	$27,548.64	50,392	4
2025-06-11	Flanagan, W. Michael	Officer	Chief Scientific Officer	Direct	Sale	20,000	32.88	$657,600.00	80,195	4
2025-06-02	Gallagher, Kathleen P.	Officer	Chief Program Officer	Direct	Sale	5,875	32.48	$190,820.00	50,554	4
2025-05-01	Gallagher, Kathleen P.	Officer	Chief Program Officer	Direct	Sale	5,875	32.40	$190,350.00	50,554	4
2025-04-01	Gallagher, Kathleen P.	Officer	Chief Program Officer	Direct	Sale	5,875	27.83	$163,501.25	50,554	4
2025-03-20	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	7,778	31.06	$241,584.68	97,130	4
2025-03-20	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	31,540	31.06	$979,632.40	305,871	4
2025-03-20	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	7,935	31.06	$246,461.10	96,720	4
2025-03-20	Flanagan, W. Michael	Officer	Chief Scientific Officer	Direct	Sale	11,780	31.06	$365,886.80	80,195	4
2025-03-20	Hughes, Steven George	Officer	Chief Medical Officer	Direct	Sale	9,578	31.06	$297,492.68	72,850	4
2025-03-11	Flanagan, W. Michael	Officer	Chief Scientific Officer	Direct	Sale	20,000	30.13	$602,600.00	91,975	4
2025-03-03	Gallagher, Kathleen P.	Officer	Chief Program Officer	Direct	Sale	5,875	29.41	$172,783.75	50,554	4
2025-02-03	Gallagher, Kathleen P.	Officer	Chief Program Officer	Direct	Sale	5,875	32.16	$188,940.00	50,554	4
2025-01-22	Gallagher, Kathleen P.	Officer	Chief Program Officer	Direct	Sale	5,629	30.16	$169,770.64	50,554	4
2025-01-21	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	10,397	28.59	$297,250.23	337,411	4
2025-01-21	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	3,287	28.59	$93,975.33	104,655	4
2025-01-21	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	2,959	28.60	$84,627.40	104,908	4
2025-01-21	Levin, Arthur A	Director	-	Direct	Sale	1,872	28.60	$53,539.20	12,958	4
2025-01-21	Flanagan, W. Michael	Officer	Chief Scientific Officer	Direct	Sale	5,672	28.60	$162,219.20	91,975	4
2025-01-21	Hughes, Steven George	Officer	Chief Medical Officer	Direct	Sale	3,947	28.60	$112,884.20	82,428	4
2024-12-18	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	11,151	32.66	$364,191.66	82,942	4
2024-12-18	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	31,855	32.66	$1,040,384.30	265,308	4
2024-12-18	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	11,151	32.66	$364,191.66	82,867	4
2024-12-18	Flanagan, W. Michael	Officer	CSTO	Direct	Sale	12,742	32.66	$416,153.72	72,647	4
2024-12-16	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	25,000	33.26	$831,500.00	94,018	4
2024-12-11	Flanagan, W. Michael	Officer	CSTO	Direct	Sale	24,000	35.77	$858,480.00	85,389	4
2024-11-19	Levin, Arthur A	Director	-	Direct	Sale	3,323	42.12	$139,964.76	14,830	4
2024-11-18	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	25,000	41.14	$1,028,500.00	94,018	4
2024-11-06	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	106,319	45.63	$4,851,335.97	94,093	4
2024-10-21	Levin, Arthur A	Director	-	Direct	Sale	5,000	46.63	$233,150.00	14,830	4
2024-10-16	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	25,000	48.52	$1,213,000.00	94,018	4
2024-10-07	Thompson, Tamar	Director	-	Direct	Sale	30,000	44.98	$1,349,400.00	0	4
2024-10-01	Flanagan, W. Michael	Officer	CSTO	Direct	Sale	62,500	47.62	$2,976,250.00	85,389	4
2024-09-23	Flanagan, W. Michael	Officer	CSTO	Direct	Sale	25,000	43.94	$1,098,500.00	72,718	4
2024-09-23	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	32,880	44.00	$1,446,720.00	234,663	4
2024-09-23	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	13,153	44.00	$578,732.00	69,018	4
2024-09-23	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	11,510	44.00	$506,440.00	96,355	4
2024-09-19	Levin, Arthur A	Director	-	Direct	Sale	5,000	45.73	$228,650.00	14,830	4
2024-09-11	Flanagan, W. Michael	Officer	CSTO	Direct	Sale	111,394	40.40	$4,500,317.60	60,871	4
2024-09-11	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	25,000	40.40	$1,010,000.00	57,171	4
2024-08-19	Levin, Arthur A	Director	-	Direct	Sale	5,000	45.19	$225,950.00	14,830	4
2024-08-06	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	28,000	43.35	$1,213,800.00	205,043	4
2024-07-19	Levin, Arthur A	Director	-	Direct	Sale	5,000	45.01	$225,050.00	14,830	4
2024-07-09	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	28,000	39.93	$1,118,040.00	205,043	4
2024-06-20	Levin, Arthur A	Director	-	Direct	Sale	5,000	37.59	$187,950.00	14,830	4
2024-06-18	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	11,228	39.13	$439,351.64	57,865	4
2024-06-18	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	9,864	39.13	$385,978.32	32,171	4
2024-06-18	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	32,074	39.13	$1,255,055.62	142,543	4
2024-06-18	Flanagan, W. Michael	Officer	CSTO	Direct	Sale	10,106	39.13	$395,447.78	50,765	4
2024-06-14	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	35,767	40.08	$1,433,541.36	112,117	4
2024-06-13	Levin, Arthur A	Director	-	Indirect	Sale	60,000	40.08	$2,404,800.00	153,872	4
2024-06-12	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	104,245	35.72	$3,723,631.40	44,093	4
2024-06-04	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	28,000	27.42	$767,760.00	112,117	4
2024-05-20	Levin, Arthur A	Director	-	Direct	Sale	5,000	29.90	$149,500.00	14,830	4
2024-05-14	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	75,000	28.28	$2,121,000.00	44,093	4
2024-05-07	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	28,000	25.54	$715,120.00	112,117	4
2024-04-19	Levin, Arthur A	Director	-	Direct	Sale	5,000	22.82	$114,100.00	14,830	4
2024-04-03	Levin, Arthur A	Director	-	Indirect	Sale	20,000	27.11	$542,200.00	253,872	4
2024-04-02	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	28,000	26.25	$735,000.00	112,117	4
2024-03-19	Levin, Arthur A	Director	-	Direct	Sale	5,000	23.97	$119,850.00	14,830	4
2024-03-13	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	40,000	24.52	$980,800.00	44,093	4
2024-03-12	Levin, Arthur A	Director	-	Direct	Sale	27,641	22.02	$608,654.82	14,830	4
2024-03-12	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	28,000	22.63	$633,640.00	112,117	4
2024-03-01	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	84,000	20.13	$1,690,920.00	112,117	4
2024-01-22	Mccarthy, Teresa	Officer	Chief Human Resources Officer	Direct	Sale	2,065	10.13	$20,918.45	17,035	4
2024-01-22	Flanagan, W. Michael	Officer	CSTO	Direct	Sale	4,129	10.13	$41,826.77	35,871	4
2024-01-22	Levin, Arthur A	Director	-	Direct	Sale	1,859	10.13	$18,831.67	17,471	4
2024-01-22	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	5,092	10.13	$51,581.96	44,008	4
2024-01-22	Maclean, Michael F	Officer	Chief Financial Officer	Direct	Sale	1,616	10.13	$16,370.08	16,884	4
2023-03-15	Levin, Arthur A	Director	-	Direct	Sale	100	22.01	$2,201.00	19,330	4
2023-02-14	Levin, Arthur A	Officer	Chief Scientific Officer	Direct	Sale	10,000	23.93	$239,300.00	19,330	4
2023-02-03	Boyce, Sarah	Director,Officer	President and CEO	Direct	Sale	3,221	24.26	$78,141.46	53,352	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

0.01%

Inst. Shares: 8,000

Shares Outstanding: 137,710,000

2025-12-31

99.24%

Inst. Shares: 136,659,089

Shares Outstanding: 137,710,000

2025-09-30

108.42%

Inst. Shares: 149,508,266

Shares Outstanding: 137,895,000

2025-06-30

95.31%

Inst. Shares: 123,547,886

Shares Outstanding: 129,622,000

2025-03-31

93.20%

Inst. Shares: 120,449,502

Shares Outstanding: 129,232,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	8,000	137,710,000	0.01%
2025-12-31	136,659,089	137,710,000	99.24%
2025-09-30	149,508,266	137,895,000	108.42%
2025-06-30	123,547,886	129,622,000	95.31%
2025-03-31	120,449,502	129,232,000	93.20%
2024-12-31	115,657,891	111,582,000	103.65%
2024-09-30	113,424,761	123,375,000	91.93%
2024-06-30	100,081,279	106,928,000	93.60%
2024-03-31	81,337,783	87,212,000	93.26%
2023-12-31	62,404,540	73,012,000	85.47%
2023-09-30	73,686,164	74,097,000	99.45%
2023-06-30	73,365,405	71,390,000	102.77%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Avidity Biosciences, Inc. (RNAM) — SEC Financial Statements & Analysis

Avidity Biosciences, Inc. (RNAM) is a pharmaceutical preparations company, incorporated in DE. Avidity Biosciences, Inc. trades on Nasdaq as: RNAM, RNA. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), Avidity Biosciences, Inc. reported a 72.11% year-over-year revenue growth, a Debt-to-Equity ratio of 0.16x. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 72.11%
Debt To Equity: 0.16x

Data as of 2025-12-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Avidity Biosciences, Inc. in?

Avidity Biosciences, Inc. (RNAM) operates in the Pharmaceutical Preparations industry.

What exchange does RNAM trade on?

Avidity Biosciences, Inc. (RNAM) trades on the Nasdaq.

Where is Avidity Biosciences, Inc. incorporated?

Avidity Biosciences, Inc. is incorporated in DE.